Immunoreactivity for the Rspo1 antigens was observed in 28% (14/50) of the patients with WHO Grade I glioma, 36.36% (20/55) of the patients with WHO Grade II glioma, 48.38% (30/62) of the patients with WHO Grade III glioma, 55.88% (38/68) of the patients with WHO Grade IV glioma and 7.5% (3/40) of normal brain tissues from automobile accident victims without glioma (Fig. 1A). The gene discussed is RSPO1; the disease is central nervous system cancer.